Hamdy Singab
Cairo, 11517, Egypt
NCT Number: NCT05306483
The aim of this study is to compare Safety, efiicacy and clinical effects of surgical versus transcatheter closure of ventricular septal defect (VSD ).
The outcome of interest is success rate, residual shunts, effect on tricuspid and aortic valves, need for blood transfusion, length of hospital and intensive care unit ( ICU ) stay, complications especially complete heart block, affection of kidney functions due to the procedure length caused by Cardiopulmonary bypass in case of surgical group or by the dye used in the group of transcatheter closure.
Looking for future studies?
Notify Me6 month–18 year
All sexes
Interventional
Not applicable
Cairo, 11517, Egypt
Both of transcatheter and surgical closure of VSD is a well-established procedure. Despite the wide using of both procedures, there is a defect in the evidence comparing the short-term outcome and the value of both techniques. Our multicenter study aims to compare the immediate outcome of both procedures in Egypt.
Superiority of one procedure over the other is still an issue of debate. Consecutively, it is now possible to compare the outcome of both techniques as the data comparing the outcome of them are so limited.
Patients and Methods/ Subjects and Methods/ Material and Methods. Type of Study: Prospective purposed comparative study.
The study will be conducted at both of Academic institute of cardiac surgery and National Heart Institute.
Study Period: One year. Start point: Once the protocol approved from the ethical committee.
Study Population:
The population of study is divided into two groups, Patients undergoing surgical VSD closure group(control group) & Patients undergoing catheter VSD closure group.
All patients will be evaluated by independent cardiologist.
Sample Size:
72 patients divided into 36 patients in each group using pass 2 program for sample size calculation according to previous literature(12). setting power at 80%, α error at 0.05.
All the following will be applied:
Note: my role is only to observe and assist only.Each patient in both groups would be subjected to:
I. Interatrial septum. II. Interventricular septal defects (number, size and site). III. Left Ventricle dimensions, volume and systolic function. IV. All cardiac valves morphology and flow. V. Right ventricle size &systolic function by TAPSE. VI. Estimated Right ventricular systolic pressure (RVSP ) using tricuspid regurgitation (TR) jet and/or estimated mean pulmonary artery pressure (PAP) using PR regurgitation jet.
▪ Surgical closure of VSD: Surgical closure would be done under general anesthesia, hypothermic cardiopulmonary bypass and cardioplegic arrest. Chest would be opened through standard median sternotomy (13). Surgical techniques would be determined according to the nature of every defect and includes direct closure, patch closure which involves. All patients will be transferred to the ICU for further follow up and management.
▪ Transcatheter closure of VSD: done for more detailed assessment of the defect size, to guide the procedure and for proper assessment after device positioning yet before its release. the use of autologous pericardium; however, polyethylene terephthalate (Dacron; C.R Bard, Haverhill, MA) and expanded polytetrafluoroethylene (Gore-Tex; W.L. Gore & Associates, Inc., AZ) may be occasionally used. These patches are held with continuous or interrupted sutures. Direct closure (without a patch may be done for the very small defects14. Most VSDs would be repaired through right atriotomy to avoid the undesirable effects of ventriculostomies(14). Under general anesthesia, patients will be fully heparinized (100 IU/Kg) with follow up by activated clotting time. Intraoperative TEE will be relation to the surrounding structures especially the distance from the tricuspid and the aortic valves
Left ventricular angiogram will be done in left anterior oblique (LAO ) 60 degree , cranial 30 degree projection to define location and size of the defect. Accordingly, proper selection of the device size(15) . Only FDA approved devices would be used, after release of the device left ventricular angiography will assure proper device positioning, and transoesophageal (TEE ) or trans thoracic echocardiograph(TTE) will be used to assess nearby structures and nearby valvular flow.
All the patients will recover from the general anesthesia, then transmitted to the ICU for follow up.
The patients of each group will have all the routine labs repeated, 12 leads electrocardiogram (ECG), complete TTE and chest x-ray, all these data will be analyzed.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ventricular septal defect closure surgery
Other names: patients undergoing surgical VSD closure
Catheter closure of VSD
Other names: Patients undergoing VSD trans catheter
Time frame: One year
two-dimensional Transthoracic Echocardiography for Detection of persistent residual Ventricular septal defect shunt flow - physiological parameter
Time frame: One year
Transthoracic Echocardiography detection of change or damage in tricuspid or aortic valve - physiological parameter
Time frame: One week postoperative
Bleeding
Time frame: One month
Postoperative complaints need more hospital or ICU stay
Time frame: One month
Electrocardiogram ECG to detect type of heart block and degree of the damage to conducting pathways - physiological parameter
Ain Shams University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07323979
CHD, Cardiovascular Abnormalities
Guangzhou, Guangdong, China
View Trial DetailsNCT04769167
Autoimmune Diseases, Cardiovascular Abnormalities
St Louis, Missouri, United States
View Trial DetailsNCT02987387
Aortic Valve Disease, Cardiovascular Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06609707
Behavior, Cardiovascular Abnormalities
Cincinnati, Ohio, United States
View Trial Details